0000000000490558

AUTHOR

Catharina C. Gross

0000-0002-4872-9189

showing 7 related works from this author

Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis.

2012

Autoimmune diseases including multiple sclerosis (MS) are the result of an imbalanced immune tolerance network. Dendritic cells (DCs) are key players in both initiating immunity (immunogenic DCs) and regulating immune responses (tolerogenic DCs = tolDCs) and are potential targets for the treatment of MS. While the immunogenic potential of DCs in fighting infection and cancer has been well established, approaches that exploit their tolerogenic features to promote transplantation tolerance and autoimmunity have emerged only more recently. TolDCs usually maintain antigen-specific T-cell tolerance either directly by inducing anergy, apoptosis, or phenotype skewing or indirectly by induction of …

Malemedicine.medical_treatmentMultiple sclerosisT-LymphocytesImmunologychemical and pharmacologic phenomenaMyelin Basic ProteinImmunotherapyDendritic CellsBiologymedicine.diseasemedicine.disease_causePhenotypeImmunotherapy AdoptiveImmune toleranceAutoimmunityTransplantationImmune systemMultiple Sclerosis Relapsing-RemittingImmunityImmunologymedicineImmunology and AllergyHumansFemaleEuropean journal of immunology
researchProduct

Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells

2015

Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by imbalanced immune regulatory networks, and MS patient-derived T effector cells are inefficiently suppressed through regulatory T cells (Treg), a phenomenon known as Treg resistance. In the current study we investigated T cell function in MS patients before and after interferon-beta therapy. We compared cytokine profile, responsiveness for Treg-mediated suppression ex vivo and evaluated reactivity of T cells in vivo using a humanized mouse model. We found that CD4+ and CD8+ T cells of therapy-naive MS patients were resistant to Treg-mediated suppression. Treg resistance is associated with an augmented IL-6 product…

AdultAdolescentdiagnosisReceptor expressionT cellchemical and pharmacologic phenomenaMice SCIDAntibodies Monoclonal Humanizedmultiple sclerosisT-Lymphocytes RegulatoryCatalysisArticleInorganic ChemistryTCIRG1lcsh:ChemistryInterleukin 21Young AdultImmune systemCytotoxic T cellMedicineAnimalsHumansIL-2 receptorPhysical and Theoretical ChemistryMolecular BiologyT effector cellslcsh:QH301-705.5SpectroscopyImmunosuppression TherapyInflammationtherapybusiness.industryOrganic Chemistryimmune regulationGeneral MedicineInterferon-betaMiddle AgedReceptors Interleukin-6Computer Science ApplicationsTregmedicine.anatomical_structureAnimals Newbornlcsh:Biology (General)lcsh:QD1-999ImmunologyLeukocytes MononuclearbusinessCD8International Journal of Molecular Sciences
researchProduct

Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity

2014

Objective: Environmental conditions (eg, latitude) play a critical role in the susceptibility and severity of many autoimmune disorders, including multiple sclerosis (MS). Here, we investigated the mechanisms underlying the beneficial effects of immune regulatory processes induced in the skin by moderate ultraviolet B (UVB) radiation on central nervous system (CNS) autoimmunity. Methods: Effects of UVB light were analyzed in a murine model of CNS autoimmunity (experimental autoimmune encephalomyelitis). Additionally, patients with relapsing–remitting MS were treated with narrowband UVB phototherapy. Immunomodulatory effects were examined in skin biopsies, serum samples, and immune cells of …

integumentary systemmedicine.medical_treatmentExperimental autoimmune encephalomyelitischemical and pharmacologic phenomenaInflammationBiologymedicine.disease_causemedicine.diseaseAutoimmunityImmune toleranceInterleukin 21Immune systemCytokineNeurologyImmunityImmunologymedicineNeurology (clinical)medicine.symptomAnnals of Neurology
researchProduct

Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity

2021

Abstract Dimethyl fumarate, an approved treatment for relapsing-remitting multiple sclerosis, exerts pleiotropic effects on immune cells as well as CNS resident cells. Here, we show that dimethyl fumarate exerts a profound alteration of the metabolic profile of human CD4+ as well as CD8+ T cells and restricts their antioxidative capacities by decreasing intracellular levels of the reactive oxygen species scavenger glutathione. This causes an increase in mitochondrial reactive oxygen species levels accompanied by an enhanced mitochondrial stress response, ultimately leading to impaired mitochondrial function. Enhanced mitochondrial reactive oxygen species levels not only result in enhanced T…

AdultCD4-Positive T-LymphocytesMaleDimethyl FumarateT cellAutoimmunityCD8-Positive T-Lymphocytesmedicine.disease_causeAntioxidantsCohort StudiesMiceYoung Adultchemistry.chemical_compoundMultiple Sclerosis Relapsing-RemittingImmune systemmedicineAnimalsHumanschemistry.chemical_classificationReactive oxygen speciesDimethyl fumarateExperimental autoimmune encephalomyelitisGlutathioneMiddle Agedmedicine.diseaseCell biologyMice Inbred C57BLmedicine.anatomical_structurechemistryFemaleNeurology (clinical)Immunosuppressive AgentsOxidative stressCD8Brain
researchProduct

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells

2016

Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein–kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells.…

AdultMale0301 basic medicineEncephalomyelitis Autoimmune ExperimentalMultiple Sclerosisanimal structuresT-LymphocytesScienceMedizinGeneral Physics and AstronomyKininsCoagulation Factor XIIAdaptive ImmunityBiologymedicine.disease_causeArticleGeneral Biochemistry Genetics and Molecular BiologyReceptors Urokinase Plasminogen ActivatorAutoimmunityYoung Adult03 medical and health sciencesImmune systemddc:570medicineAnimalsHumansddc:610cardiovascular diseasesNeuroinflammationAgedFactor XIIMultidisciplinaryInterleukin-17QExperimental autoimmune encephalomyelitisCell DifferentiationDendritic CellsGeneral ChemistryMiddle Agedmedicine.diseaseAcquired immune systemMice Inbred C57BL030104 developmental biologyNeuroimmunologyFactor XIIImmunologyFemaleKallikreinscirculatory and respiratory physiologyNature Communications
researchProduct

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

2021

AbstractBackgroundMultiple sclerosis (MS) disease risk is associated with reduced sun exposure. This study assessed the relationship between measures of sun-exposure (vitamin D (vitD), latitude) and MS disease severity, the mechanisms of action, and effect-modification by medication and sun-sensitivity associated MC1R variants.MethodsTwo multi-center cohort studies (nNationMS=946, nBIONAT=991). Outcomes were the multiple sclerosis severity score (MSSS) and the number of Gd-enhancing lesion (GELs). RNAseq of four immune cell populations before and after UV-phototherapy of five MS patients.ResultsHigh serum vitD was associated with reduced MSSS (PNationMS=0.021; PBIONAT=0.007) and reduced ris…

medicine.medical_specialty610 Medicine & healthDiseaseGastroenterologyLesionImmune systemInterferonInternal medicineVitamin D and neurologyMedicineddc:610610 Medicine & healthBeneficial effectsSunlightSystemic lupus erythematosusMultidisciplinaryLow latitudebusiness.industryMultiple sclerosismedicine.diseaseddc:Cardiovascular and Metabolic DiseasesDisease riskmedicine.symptombusinessmedicine.drugCohort study
researchProduct

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients

2020

Background: Progressive multifocal leukoencephalopathy (PML) can in rare cases occur in natalizumab-treated patients with high serum anti-JCPyV antibodies, hypothetically due to excessive blockade of immune cell migration. Objective: Immune cell recruitment to the central nervous system (CNS) was assessed in relapsing-remitting multiple sclerosis (RRMS) patients stratified by low versus high anti-JCPyV antibody titers as indicator for PML risk. Methods: Cerebrospinal fluid (CSF) cell counts of 145 RRMS patients were quantified by flow cytometry. Generalized linear models were employed to assess influence of age, sex, disease duration, Expanded Disability Status Scale (EDSS), clinical/radiol…

CellCell Countprogressive multifocal leukoencephalopathycerebrospinal fluidMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineNatalizumabCerebrospinal fluidmedicineHumansJCV index030304 developmental biology0303 health sciencesbiologybusiness.industryNatalizumabMultiple sclerosisProgressive multifocal leukoencephalopathyLeukoencephalopathy Progressive MultifocalJCPyVmedicine.diseaseJC VirusCSF cell countstissue-resident memory cellsBlockadeclinical activityTitermedicine.anatomical_structureNeurologyImmunologybiology.proteinNeurology (clinical)AntibodybusinessOriginal Research Papers030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct